How does the industry begin to address the remaining 10,000 human diseases?
Nearly two years ago, Medable CEO Michelle Longmire posed this question in a blog titled "Accelerating the journey from possibility to validation in new drug development." At the time, she emphasized that harnessing the most impactful tools available would foster fresh synergies at the intersection of safety, scientific innovation, and swiftness, potentially ushering in a new era of pharmaceutical development.
Today, our industry teeters on the edge of a new era in clinical research, marked by rapid advancements in technologies commonly known as artificial intelligence and machine learning (AI and ML). Although both of these technologies have been around for some time, recent progress in their capabilities has thrust them into the forefront of our industry.
In the days ahead, AI and ML could very well emerge as the most pivotal technologies of our era, with the potential to facilitate genuine scalability in the pharmaceutical sector and numerous other industries. Read the full article to explore their combined potential in the industry.